Special Issue "Nanoparticles Based Nanomedicine and Vaccines Development"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 680
In recent years, the scientific and medical communities have reported the use of nanotechnology/biotechnology, nanomedicine, and vaccines on the improved management of various diseases and viruses. The early detection of the diseases and effective treatment with nanomedicine for targeted therapy has led to significant progress in accelerating precision nanomedicine applications. The use of nanobiotechnology for the development of nanomedicine to deliver small molecules, peptides, genes, and other therapeutics offer improved pharmacokinetics, pharmacodynamics, and safety profiles. The nanomedicine can be developed through encapsulation of drug into nanoparticles, conjugation of specific targeting ligand on nanoparticles, and chemical and physical interaction with multifunction properties would allow for effective therapy at early stage of diseases.
Nanobiotechnology also plays a key role in vaccines development. Especially in the last 3 years since the COVID-19 pandemic began, nanobiotechnology has offered a range of applications to deal with the pandemic world. The vaccines of COVID-19 have been developed based on nanoscaled mRNA. This showed the potential of nanobiotechnology in health care systems. Nanoparticles-based vaccines offer exceptional benefits over other vaccines. Nanoparticles-based vaccines provide safety, controlled delivery, long term stability, more efficacy toward the virus, and development of strong immune systems.
The scope of this Special Issue is to cover recent progress in nanobiotechnology as it related to nanomedicine and vaccines. A key aim is to bring the latest advances of various nanomedicine approaches for the detection and treatment of various types of diseases. Further vaccine development research is more important for treatment of COVID-19. Additionally, this issue aims to cover the nanoparticles-based drug delivery and pharmaceutical development and impact on disease prevention.
Dr. Raj Kumar
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug delivery